This finding has important implications for current therapeutic protocols that involve the clinical use of this JAK3 inhibitor for the therapy of rheumatoid arthritis, a variety of gut associated diseases including Crohn's, ulcerative colitis and IBD [51], [86]–[89]. Here, JAK3 is linked to rheumatoid arthritis.